1	Two	CD	4	num
2	major	JJ	4	amod
3	drug	NN	4	nn
4	companies	NNS	5	nsubj
5	posted	VBD	0	root
6	strong	JJ	8	amod
7	third-quarter	NN	8	nn
8	earnings	NNS	5	dobj
9	,	,	5	punct
10	in	IN	5	prep
11	line	NN	10	pobj
12	with	IN	11	prep
13	profits	NNS	12	pobj
14	already	RB	15	advmod
15	reported	VBN	13	partmod
16	by	IN	15	prep
17	industry	NN	18	nn
18	leaders	NNS	16	pobj
19	and	CC	13	cc
20	analysts	NNS	22	poss
21	'	POS	20	possessive
22	expectations	NNS	13	conj
23	.	.	5	punct

1	But	CC	10	cc
2	Pfizer	NNP	3	nn
3	Inc.	NNP	10	nsubj
4	,	,	3	punct
5	based	VBN	3	partmod
6	in	IN	5	prep
7	New	NNP	8	nn
8	York	NNP	6	pobj
9	,	,	3	punct
10	reported	VBD	0	root
11	flat	JJ	12	amod
12	earnings	NNS	10	dobj
13	.	.	10	punct

1	Schering-Plough	NNP	2	nn
2	Corp.	NNP	10	nsubj
3	,	,	2	punct
4	based	VBN	2	partmod
5	in	IN	4	prep
6	Madison	NNP	5	pobj
7	,	,	6	punct
8	N.J.	NNP	6	appos
9	,	,	6	punct
10	reported	VBD	0	root
11	a	DT	14	det
12	21	CD	13	number
13	%	NN	14	amod
14	rise	NN	10	dobj
15	in	IN	14	prep
16	earnings	NNS	15	pobj
17	as	IN	25	mark
18	American	NNP	20	nn
19	Home	NNP	20	nn
20	Products	NNPS	21	nn
21	Corp.	NNP	25	nsubj
22	of	IN	21	prep
23	New	NNP	24	nn
24	York	NNP	22	pobj
25	posted	VBD	10	advcl
26	an	DT	29	det
27	11	CD	28	number
28	%	NN	29	amod
29	increase	NN	25	dobj
30	in	IN	29	prep
31	net	NN	30	pobj
32	.	.	10	punct

1	American	NNP	3	nn
2	Home	NNP	3	nn
3	Products	NNPS	0	root

1	American	NNP	3	nn
2	Home	NNP	3	nn
3	Products	NNPS	4	nsubj
4	said	VBD	0	root
5	sales	NNS	15	nsubj
6	and	CC	5	cc
7	earnings	NNS	5	conj
8	for	IN	5	prep
9	the	DT	11	det
10	third	JJ	11	amod
11	quarter	NN	8	pobj
12	and	CC	11	cc
13	nine	CD	14	num
14	months	NNS	11	conj
15	were	VBD	4	ccomp
16	at	IN	15	prep
17	record	NN	18	nn
18	levels	NNS	16	pobj
19	.	.	4	punct

1	Sales	NNS	6	nsubj
2	for	IN	1	prep
3	the	DT	5	det
4	third	JJ	5	amod
5	quarter	NN	2	pobj
6	increased	VBD	0	root
7	6.5	CD	8	num
8	%	NN	6	dobj
9	to	TO	6	prep
10	$	$	9	pobj
11	1.51	CD	10	number
12	billion	CD	10	number
13	from	IN	6	prep
14	$	$	13	pobj
15	1.42	CD	14	number
16	billion	CD	14	number
17	.	.	6	punct

1	Sales	NNS	5	nsubj
2	of	IN	1	prep
3	health-care	JJ	4	amod
4	products	NNS	2	pobj
5	increased	VBD	0	root
6	6	CD	7	num
7	%	NN	5	dobj
8	in	IN	5	prep
9	the	DT	11	det
10	third	JJ	11	amod
11	quarter	NN	8	pobj
12	,	,	5	punct
13	based	VBN	5	prep
14	in	IN	13	pcomp
15	part	NN	14	pobj
16	on	IN	13	prep
17	strong	JJ	18	amod
18	sales	NNS	16	pobj
19	of	IN	18	prep
20	prescription	NN	21	nn
21	drugs	NNS	19	pobj
22	such	JJ	23	mwe
23	as	IN	21	prep
24	Premarin	NNP	23	pobj
25	,	,	24	punct
26	an	DT	28	det
27	estrogen-replacement	NN	28	nn
28	drug	NN	24	appos
29	,	,	24	punct
30	and	CC	18	cc
31	sales	NNS	18	conj
32	of	IN	31	prep
33	the	DT	34	det
34	company	NN	37	poss
35	's	POS	34	possessive
36	infant	NN	37	nn
37	formula	NN	32	pobj
38	.	.	5	punct

1	American	NNP	3	nn
2	Home	NNP	3	nn
3	Products	NNPS	4	nsubj
4	said	VBD	0	root
5	net	JJ	6	amod
6	income	NN	7	nsubj
7	benefited	VBD	4	ccomp
8	from	IN	7	prep
9	a	DT	14	det
10	``	``	14	punct
11	lower	JJR	14	amod
12	effective	JJ	14	amod
13	tax	NN	14	nn
14	rate	NN	8	pobj
15	,	,	14	punct
16	''	''	14	punct
17	reflecting	VBG	14	partmod
18	a	DT	19	det
19	reduction	NN	17	dobj
20	of	IN	19	prep
21	foreign	JJ	23	amod
22	tax	NN	23	nn
23	rates	NNS	20	pobj
24	,	,	14	punct
25	and	CC	14	cc
26	additional	JJ	27	amod
27	operations	NNS	14	conj
28	in	IN	27	prep
29	Puerto	NNP	30	nn
30	Rico	NNP	28	pobj
31	.	.	4	punct

1	Net	NN	4	nsubjpass
2	also	RB	4	advmod
3	was	VBD	4	auxpass
4	aided	VBN	0	root
5	by	IN	4	prep
6	a	DT	7	det
7	gain	NN	5	pobj
8	on	IN	7	prep
9	the	DT	10	det
10	sale	NN	8	pobj
11	of	IN	10	prep
12	the	DT	13	det
13	company	NN	16	poss
14	's	POS	13	possessive
15	equity	NN	16	nn
16	interests	NNS	11	pobj
17	in	IN	16	prep
18	South	NNP	19	nn
19	Africa	NNP	17	pobj
20	effective	JJ	7	amod
21	Sept.	NNP	20	tmod
22	1	CD	21	num
23	.	.	4	punct

1	In	IN	13	prep
2	New	NNP	3	nn
3	York	NNP	5	nn
4	Stock	NNP	5	nn
5	Exchange	NNP	7	nn
6	composite	JJ	7	amod
7	trading	NN	1	pobj
8	yesterday	NN	13	tmod
9	,	,	13	punct
10	American	NNP	12	nn
11	Home	NNP	12	nn
12	Products	NNPS	13	nsubj
13	closed	VBD	0	root
14	at	IN	13	prep
15	$	$	14	pobj
16	102.25	CD	15	num
17	a	DT	18	det
18	share	NN	15	npadvmod
19	,	,	13	punct
20	down	IN	13	advmod
21	75	CD	22	num
22	cents	NNS	20	pobj
23	.	.	13	punct

1	Pfizer	NNP	0	erased

1	Pfizer	NNP	2	nsubj
2	said	VBD	0	root
3	third-quarter	NN	4	nn
4	sales	NNS	5	nsubj
5	increased	VBD	2	ccomp
6	4	CD	7	num
7	%	NN	5	dobj
8	to	TO	5	prep
9	$	$	8	pobj
10	1.44	CD	9	number
11	billion	CD	9	number
12	from	IN	5	prep
13	$	$	12	pobj
14	1.38	CD	13	number
15	billion	CD	13	number
16	.	.	2	punct

1	The	DT	2	det
2	company	NN	3	nsubj
3	said	VBD	0	root
4	net	JJ	5	amod
5	income	NN	7	nsubj
6	was	VBD	7	cop
7	flat	JJ	3	ccomp
8	because	IN	9	mwe
9	of	IN	7	prep
10	investment	NN	9	pobj
11	in	IN	10	prep
12	research	NN	11	pobj
13	and	CC	12	cc
14	development	NN	12	conj
15	and	CC	10	cc
16	costs	NNS	10	conj
17	related	VBN	16	amod
18	to	TO	17	prep
19	launches	NNS	18	pobj
20	of	IN	19	prep
21	several	JJ	22	amod
22	products	NNS	20	pobj
23	.	.	3	punct

1	The	DT	2	det
2	company	NN	3	nsubj
3	said	VBD	0	root
4	the	DT	5	det
5	dollar	NN	9	nsubj
6	's	POS	5	possessive
7	continued	VBN	5	amod
8	strengthening	VBG	5	amod
9	reduced	VBD	3	ccomp
10	world-wide	JJ	12	amod
11	sales	NNS	12	nn
12	growth	NN	9	dobj
13	by	IN	9	prep
14	three	CD	16	num
15	percentage	NN	16	nn
16	points	NNS	13	pobj
17	.	.	3	punct

1	Pfizer	NNP	2	nsubj
2	posted	VBD	0	root
3	its	PRP$	5	poss
4	largest	JJS	5	amod
5	gains	NNS	2	dobj
6	in	IN	5	prep
7	healthcare	NN	8	nn
8	sales	NNS	6	pobj
9	,	,	8	punct
10	up	IN	8	advmod
11	3	CD	12	num
12	%	NN	10	pobj
13	,	,	8	punct
14	and	CC	8	cc
15	consumer	NN	16	nn
16	products	NNS	8	conj
17	,	,	16	punct
18	up	IN	16	advmod
19	23	CD	20	num
20	%	NN	18	pobj
21	.	.	2	punct

1	Sales	NNS	11	nsubj
2	by	IN	1	prep
3	the	DT	9	det
4	specialty	NN	5	nn
5	chemicals	NNS	9	nn
6	and	CC	5	cc
7	materials	NNS	8	nn
8	science	NN	5	conj
9	segments	NNS	2	pobj
10	were	VBD	11	cop
11	flat	JJ	0	root
12	,	,	11	punct
13	and	CC	11	cc
14	sales	NNS	19	nsubj
15	by	IN	14	prep
16	the	DT	18	det
17	agriculture	NN	18	nn
18	segment	NN	15	pobj
19	declined	VBD	11	conj
20	5	CD	21	num
21	%	NN	19	dobj
22	.	.	11	punct

1	In	IN	8	prep
2	the	DT	4	det
3	health-care	JJ	4	amod
4	segment	NN	1	pobj
5	,	,	8	punct
6	pharmaceutical	JJ	7	amod
7	sales	NNS	8	nsubj
8	increased	VBD	0	root
9	4	CD	10	num
10	%	NN	8	dobj
11	and	CC	8	cc
12	sales	NNS	16	nsubj
13	of	IN	12	prep
14	hospital	NN	15	nn
15	products	NNS	13	pobj
16	increased	VBD	8	conj
17	1	CD	18	num
18	%	NN	16	dobj
19	.	.	8	punct

1	During	IN	6	prep
2	the	DT	3	det
3	quarter	NN	1	pobj
4	,	,	6	punct
5	Pfizer	NNP	6	nsubj
6	received	VBD	0	root
7	federal	JJ	8	amod
8	approval	NN	6	dobj
9	of	IN	8	prep
10	Procardia	NNP	11	nn
11	XL	NNP	9	pobj
12	,	,	11	punct
13	a	DT	16	det
14	calcium	NN	15	nn
15	channel	NN	16	nn
16	blocker	NN	11	appos
17	approved	VBN	16	partmod
18	for	IN	17	prep
19	both	DT	20	preconj
20	angina	NN	18	pobj
21	and	CC	20	cc
22	hypertension	NN	20	conj
23	,	,	11	punct
24	and	CC	11	cc
25	Monorail	NNP	26	nn
26	Piccolino	NNP	11	conj
27	,	,	26	punct
28	used	VBN	26	partmod
29	to	TO	30	aux
30	open	VB	28	xcomp
31	obstructed	VBN	33	amod
32	coronary	JJ	33	amod
33	arteries	NNS	30	dobj
34	.	.	6	punct

1	In	IN	11	prep
2	New	NNP	3	nn
3	York	NNP	5	nn
4	Stock	NNP	5	nn
5	Exchange	NNP	7	nn
6	composite	JJ	7	amod
7	trading	NN	1	pobj
8	yesterday	NN	11	tmod
9	,	,	11	punct
10	Pfizer	NNP	11	nsubj
11	closed	VBD	0	root
12	at	IN	11	prep
13	$	$	12	pobj
14	67.75	CD	13	num
15	a	DT	16	det
16	share	NN	13	npadvmod
17	,	,	11	punct
18	up	IN	11	advmod
19	75	CD	20	num
20	cents	NNS	18	pobj
21	.	.	11	punct

1	Schering-Plough	NNP	0	erased

1	Schering-Plough	NNP	2	nsubj
2	said	VBD	0	root
3	sales	NNS	4	nsubj
4	gained	VBD	2	ccomp
5	2.7	CD	6	num
6	%	NN	4	dobj
7	to	TO	4	prep
8	$	$	7	pobj
9	743.7	CD	8	number
10	million	CD	8	number
11	from	IN	4	prep
12	$	$	11	pobj
13	724.4	CD	12	number
14	million	CD	12	number
15	.	.	2	punct

1	In	IN	7	prep
2	the	DT	3	det
3	period	NN	1	pobj
4	,	,	7	punct
5	the	DT	6	det
6	company	NN	7	nsubj
7	completed	VBD	0	root
8	the	DT	9	det
9	sale	NN	7	dobj
10	of	IN	9	prep
11	its	PRP$	14	poss
12	European	JJ	14	amod
13	cosmetics	NNS	14	nn
14	businesses	NNS	10	pobj
15	,	,	7	punct
16	sold	VBD	7	conj
17	a	DT	19	det
18	majority	NN	19	nn
19	interest	NN	16	dobj
20	in	IN	19	prep
21	its	PRP$	23	poss
22	Brazilian	JJ	23	amod
23	affiliate	NN	20	pobj
24	,	,	7	punct
25	and	CC	7	cc
26	announced	VBD	7	conj
27	the	DT	28	det
28	reorganization	NN	26	dobj
29	of	IN	28	prep
30	its	PRP$	33	poss
31	over-the-counter	JJ	33	amod
32	drug	NN	33	nn
33	businesses	NNS	29	pobj
34	into	IN	28	prep
35	a	DT	37	det
36	new	JJ	37	amod
37	unit	NN	34	pobj
38	,	,	37	punct
39	Schering-Plough	NNP	42	nn
40	Health	NNP	41	nn
41	Care	NNP	42	nn
42	Products	NNPS	37	appos
43	.	.	7	punct

1	These	DT	2	det
2	actions	NNS	5	nsubj
3	did	VBD	5	aux
4	n't	RB	5	neg
5	affect	VB	0	root
6	results	NNS	5	dobj
7	because	IN	19	mark
8	the	DT	9	det
9	gain	NN	19	nsubjpass
10	on	IN	9	prep
11	the	DT	12	det
12	sale	NN	10	pobj
13	of	IN	12	prep
14	the	DT	17	det
15	European	JJ	17	amod
16	cosmetics	NNS	17	nn
17	businesses	NNS	13	pobj
18	was	VBD	19	auxpass
19	offset	VBN	5	advcl
20	by	IN	19	prep
21	provisions	NNS	20	pobj
22	relating	VBG	21	partmod
23	to	TO	22	prep
24	the	DT	26	det
25	Brazil	NNP	26	nn
26	divestiture	NN	23	pobj
27	and	CC	26	cc
28	drug	NN	29	nn
29	restructuring	NN	26	conj
30	.	.	5	punct

1	U.S.	NNP	3	nn
2	pharmaceutical	JJ	3	amod
3	sales	NNS	4	nsubj
4	rose	VBD	0	root
5	15	CD	6	num
6	%	NN	4	dobj
7	,	,	4	punct
8	led	VBN	4	partmod
9	by	IN	8	prep
10	allergy	NN	12	conj
11	,	,	12	punct
12	asthma	NN	15	nn
13	and	CC	12	cc
14	cold	JJ	12	conj
15	products	NNS	9	pobj
16	;	:	15	punct
17	dermatological	JJ	18	amod
18	products	NNS	15	conj
19	;	:	15	punct
20	anti-infectives	NNS	15	conj
21	and	CC	20	cc
22	anti-cancer	JJ	23	amod
23	products	NNS	20	conj
24	;	:	15	punct
25	and	CC	15	cc
26	cardiovascular	JJ	27	amod
27	products	NNS	15	conj
28	.	.	4	punct

1	World-wide	JJ	4	amod
2	consumer	NN	3	nn
3	product	NN	4	nn
4	sales	NNS	5	nsubj
5	declined	VBD	0	root
6	12	CD	7	num
7	%	NN	5	dobj
8	,	,	5	punct
9	primarily	RB	11	advmod
10	because	IN	11	mwe
11	of	IN	5	prep
12	the	DT	15	det
13	European	JJ	15	amod
14	cosmetics	NNS	15	nn
15	sale	NN	11	pobj
16	.	.	5	punct

1	Significantly	RB	2	advmod
2	lower	JJR	3	amod
3	sales	NNS	14	nsubj
4	of	IN	3	prep
5	`	``	7	punct
6	Stay	NNP	7	nn
7	Trim	NNP	10	nn
8	'	''	7	punct
9	diet	NN	10	nn
10	aids	NNS	4	pobj
11	also	RB	14	advmod
12	were	VBD	14	cop
13	a	DT	14	det
14	factor	NN	0	root
15	in	IN	14	prep
16	the	DT	17	det
17	drop	NN	15	pobj
18	.	.	14	punct

1	The	DT	5	det
2	Maybelline	NNP	5	nn
3	beauty	NN	4	nn
4	product	NN	5	nn
5	line	NN	6	nsubj
6	had	VBD	0	root
7	higher	JJR	8	amod
8	sales	NNS	6	dobj
9	following	VBG	6	prep
10	a	DT	13	det
11	sluggish	JJ	13	amod
12	first	JJ	13	amod
13	half	NN	9	pobj
14	.	.	6	punct

1	In	IN	9	prep
2	Big	NNP	3	nn
3	Board	NNP	5	nn
4	composite	JJ	5	amod
5	trading	NN	1	pobj
6	,	,	9	punct
7	Schering-Plough	NNP	8	nn
8	shares	NNS	9	nsubj
9	fell	VBD	0	root
10	75	CD	11	num
11	cents	NNS	9	dobj
12	to	TO	13	aux
13	close	VB	9	xcomp
14	at	IN	13	prep
15	$	$	14	pobj
16	74.125	CD	15	num
17	.	.	9	punct


